Yazar "Bes, Cemal" için listeleme
-
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
Kimyon, G.; Kalyoncu, Umut; Kiraz, Sedat; Bes, Cemal; Coşkun, Necdet; Yagiz, B.; Kelesoglu, B.; Mercan, Rıdvan (Clinical and Experimental Rheumatology S.A.S., 2021)Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ... -
Biosimilar Infliximab Experience in Spondyloartritis Patients: Treasure Real Life Results
Bilge, Nazife Sule Yasar; Kaşifoğlu, Timuçin; Kiraz, Sedat; Ertenli, Ali İhsan; Dalkılıç, E.; Bes, Cemal; Kalyoncu, Umut; Mercan, Rıdvan (Bmj Publishing Group, 2020)[No Abstract Available] -
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
Kimyon, Gezmiş; Kiraz, Sedat; Ertenli, Ihsan; Küçükşahin, Orhan; Dalkılıç, Ediz; Bes, Cemal; Kalyoncu, Umut; Mercan, Rıdvan (Wiley, 2018)[No Abstract Available] -
Methodology of a new inflammatory arthritis registry: TReasure
Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali İhsan; Dalkılıç, Hüseyin Ediz; Bes, Cemal; Küçükşahin, Orhan; Kiraz, Sedat; Mercan, Rıdvan (Tubitak Scientific & Technical Research Council Turkey, 2018)Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry ...